Is it sufficient to maintain patients with atrial fibrillation and established PAD on a DOAC or VKA alone, or is there an additional benefit to adding an antiplatelet agent for CVD benefit?

Is it sufficient to maintain patients with atrial fibrillation and established PAD on a DOAC or VKA alone, or is there an additional benefit to adding an antiplatelet agent for CVD benefit?

• Yes, maintaining on a DOAC or VKA alone is sufficient for these patients
• No, there is an additional benefit to adding an antiplatelet agent in all such patients
• No, an antiplatelet agent should be added only for patients with low bleeding risk and high-risk disease features (e.g., remote CABG with occluded grafts, s/p left main PCI, multiple vascular beds involved, prior stent thrombosis)
• Other